JP2023541827A - Ｇｌｐ－１受容体アゴニストの改善された医薬製剤 - Google Patents

Ｇｌｐ－１受容体アゴニストの改善された医薬製剤 Download PDF

Info

Publication number
JP2023541827A
JP2023541827A JP2023515289A JP2023515289A JP2023541827A JP 2023541827 A JP2023541827 A JP 2023541827A JP 2023515289 A JP2023515289 A JP 2023515289A JP 2023515289 A JP2023515289 A JP 2023515289A JP 2023541827 A JP2023541827 A JP 2023541827A
Authority
JP
Japan
Prior art keywords
copolymer
coating
mol
repeat units
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541827A5 (https=
JPWO2022049310A5 (https=
Inventor
フロリアン フェーガー，
マルティン ヴェルレ，
Original Assignee
サイプルメド ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイプルメド ゲーエムベーハー filed Critical サイプルメド ゲーエムベーハー
Publication of JP2023541827A publication Critical patent/JP2023541827A/ja
Publication of JP2023541827A5 publication Critical patent/JP2023541827A5/ja
Publication of JPWO2022049310A5 publication Critical patent/JPWO2022049310A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023515289A 2020-09-07 2021-09-07 Ｇｌｐ－１受容体アゴニストの改善された医薬製剤 Pending JP2023541827A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20194828 2020-09-07
EP20194828.8 2020-09-07
EP20208628 2020-11-19
EP20208628.6 2020-11-19
PCT/EP2021/074625 WO2022049310A1 (en) 2020-09-07 2021-09-07 Improved pharmaceutical formulations of glp-1 receptor agonists

Publications (3)

Publication Number Publication Date
JP2023541827A true JP2023541827A (ja) 2023-10-04
JP2023541827A5 JP2023541827A5 (https=) 2024-09-13
JPWO2022049310A5 JPWO2022049310A5 (https=) 2024-09-13

Family

ID=77821779

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515289A Pending JP2023541827A (ja) 2020-09-07 2021-09-07 Ｇｌｐ－１受容体アゴニストの改善された医薬製剤

Country Status (5)

Country Link
US (1) US20240041983A1 (https=)
EP (1) EP4210680A1 (https=)
JP (1) JP2023541827A (https=)
CN (1) CN116419750A (https=)
WO (1) WO2022049310A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
EP4429704A4 (en) 2021-11-10 2025-11-05 I2O Therapeutics Inc IONIC LIQUID COMPOSITIONS
EP4486366A1 (en) * 2022-03-03 2025-01-08 Cyprumed GmbH Improved oral pharmaceutical formulations of therapeutic peptides and proteins
WO2023209662A1 (en) * 2022-04-29 2023-11-02 Pentide Therapeutics Limited Pharmaceutical compositions of semaglutide and the methods of use thereof
CA3266547A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company COMPOSITIONS FOR ORAL ADMINISTRATION
WO2024134493A1 (en) * 2022-12-19 2024-06-27 Quisitive Therapeutics Drug delivery system for tirzepatide
US12605427B2 (en) * 2023-05-15 2026-04-21 Red Mountain Med Spa, LLC Sublingual semaglutide-BPC 157 combination for weight loss

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533656A (ja) * 2011-11-30 2014-12-15 武田薬品工業株式会社 有核錠
JP2016500682A (ja) * 2012-10-17 2016-01-14 ノヴォ ノルディスク アー／エス 経口ペプチドデリバリーのための脂肪酸アシル化アミノ酸
JP2018505172A (ja) * 2015-01-29 2018-02-22 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト及び腸溶コーティングを含む錠剤
US20200237875A1 (en) * 2019-01-30 2020-07-30 Synlev Pharmaceuticals Corporation Formulations and methods for treatment of fibromyalgia and related myofascial pain disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
AT382381B (de) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
JP2002512175A (ja) 1998-02-27 2002-04-23 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１類似体の誘導体類
EP1061946B1 (en) 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
EP1175390B1 (en) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
MXPA06006745A (es) 2003-12-18 2006-08-18 Novo Nordisk As Compuestos glp-1 novedosos.
JP2007537142A (ja) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ アルブミン様物質に結合した新規のｇｌｐ−１類似物
MXPA06015049A (es) 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
JP5755398B2 (ja) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス 伸長されたｇｌｐ−１化合物
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
RU2548807C2 (ru) 2009-05-20 2015-04-20 Торэй Индастриз, Инк. Пептиды, проникающие в клетку
ES2659442T3 (es) 2009-09-30 2018-03-15 Thiomatrix Forschungs- Und Beratungs Gmbh Polímeros mucoadhesivos con estructuras parciales de vitamina B
WO2011133198A1 (en) 2010-04-21 2011-10-27 Hosheng Tu A pharmaceutical composition of nanoparticles
GB2501219A (en) 2011-02-04 2013-10-16 Aegis Therapeutics Llc Orally bioavailable peptide drug compositions and methods thereof
WO2012140155A1 (en) 2011-04-14 2012-10-18 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
EP2861220A2 (en) 2012-06-14 2015-04-22 Entrega, Inc. Mucoadhesive devices for delivery of active agents
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN105832691B (zh) * 2016-05-31 2018-10-02 深圳市健元医药科技有限公司 一种度拉糖肽结肠定位缓释制剂及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533656A (ja) * 2011-11-30 2014-12-15 武田薬品工業株式会社 有核錠
JP2016500682A (ja) * 2012-10-17 2016-01-14 ノヴォ ノルディスク アー／エス 経口ペプチドデリバリーのための脂肪酸アシル化アミノ酸
JP2018505172A (ja) * 2015-01-29 2018-02-22 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト及び腸溶コーティングを含む錠剤
US20200237875A1 (en) * 2019-01-30 2020-07-30 Synlev Pharmaceuticals Corporation Formulations and methods for treatment of fibromyalgia and related myofascial pain disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AAPS PHARMASCI, vol. 3, no. 2, JPN6025041297, 2001, pages 14, ISSN: 0005701272 *
粉砕, JPN6025041299, 2006, pages 3 - 10, ISSN: 0005701273 *

Also Published As

Publication number Publication date
US20240041983A1 (en) 2024-02-08
WO2022049310A1 (en) 2022-03-10
EP4210680A1 (en) 2023-07-19
CN116419750A (zh) 2023-07-11

Similar Documents

Publication Publication Date Title
US20240041983A1 (en) Improved pharmaceutical formulations of glp-1 receptor agonists
US10905744B2 (en) Pharmaceutical formulations for the oral delivery of peptide drugs
Bhati et al. A detailed review on oral mucosal drug delivery system
Shaji et al. Protein and peptide drug delivery: oral approaches
US9399054B2 (en) Compositions for delivering peptide YY and PYY agonists
CN101801309B (zh) 口服递送的肽药物
US20170304195A1 (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs
KR102294577B1 (ko) 고체 경구 제형
JP2010525033A (ja) 高濃縮のインスリン溶液及び組成物
BRPI0908292B1 (pt) Métodos e composições para administração oral de exenatida
CN110662550A (zh) 生理活性物质的口服给药
WO2016004067A1 (en) Aromatic-cationic peptide formulations, compositions and methods of use
JP2022522550A (ja) 副甲状腺ホルモンアナログの経口製剤および治療
Yoshida et al. Oral drug delivery systems applied to launched products: Value for the patients and industrial considerations
EP4026566B1 (en) Oral pharmaceutical composition comprising teriparatide and method for preparing same
WO2017168245A1 (en) Pharmaceutical compositions and methods for the treatment of diabetes
US20220323544A1 (en) Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
JP2012111773A (ja) 経口吸収改善用医薬組成物
CN119454605B (zh) 一种实现多肽口服吸收的组合物
KR20250141711A (ko) 경구 투여되는 폴리펩타이드 치료제의 전신 생체이용률을 증가시키는 조성물 및 방법
EP1300155A1 (en) Enteric preparations containing physiologically active peptides
EP3999637B1 (en) Intestinal alkaline phosphatase-based treatments of metabolic disorders
US20260000620A1 (en) Oral dosage forms
Hill Pharmacokinetic analysis and formulation development of therapeutic proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406